oxaliplatin, irinotecan, S-1

DRUG2 trials

Sponsors

Hokkaido University Hospital Cancer Center, Hallym University Medical Center

Conditions

Biliary Tract Neoplasmunresectable pancreatic cancer

Phase 1

Phase 1 trial of Oxaliplatin/IRInotecan/S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancer

Active, not recruitingJPRN-UMIN000017002

Hokkaido University Hospital Cancer Centerunresectable pancreatic cancer

Start: 2015-11-02Target: 18Updated: 2026-06-29

Phase 2

Study of Oxaliplatin, Irinotecan, and S-1 in Biliary Tract Cancer

Hallym University Medical CenterBiliary Tract Neoplasm

Start: 2015-03-31End: 2017-09-30Target: 31Updated: 2017-08-23

Related Papers

Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study

BMC Cancer2021-07-1610 citations